These guidelines apply to facilities containing dealings that are required to be conducted in a PC1 facility certified by the Gene Technology Regulator.
This first issue focuses on Notifiable Low Risks Dealings (NLRDs).
The guidelines detail the requirements for, and the conditions of, accreditation.
This document provides further information about how to get accredited and how to stay accredited.
This document describes the Physical Containment (PC) levels used by the Gene Technology Regulator in the certification of facilities. It also explains the categories of organisms and types of dealings intended to be contained in each facility type and PC level.
This documents helps with the correct classification of NLRDs being included in the Record of Assessment for reporting online.
Gene technology is widely used in Australia: in agriculture, in research, in health and medicine, in education, and in industry.
Details on how the Gene Technology Regulator views requests to alter instruments of accreditation.
This guidance provides basic information to organisations in Australia wishing to conduct human clinical trials involving an experimental product that is, or contains, a genetically modified organism (GMO).
Gene technology (also known as genetic engineering or genetic modification) provides ways to make changes to genes – the sets of instructions in the cells of all living creatures. There is a large amount of overlap between ‘gene technology’ and the newer term ‘synthetic biology’.